The downregulation of ELF1 in ETS fusion positive prostate tumors could allow for increased binding of oncogenic ETS factors at these sites, leading to a subsequent activation of genes involved in various cancerous phenotypes. The gene discussed is ELF1; the disease is prostate neoplasm.